This observation is consistent with findings from clinical studies in which blockade of CXCL2 effectively reduced neutrophil numbers in severe asthmatic patients was not associated with reduction of exacerbations nor improvement in asthma control or lung function [43, 44], further suggesting that modulating pulmonary neutrophil numbers may be somewhat dissociated from achieving clinical control. Here, CXCL2 is linked to asthma.